DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156,624,290 | -6.8% | 631,295 | -9.9% | 0.42% | 0.0% |
| Q2 2023 | $168,104,880 | -8.3% | 700,437 | -3.8% | 0.42% | -9.7% |
| Q1 2023 | $183,417,321 | -9.6% | 727,731 | -4.8% | 0.46% | -17.6% |
| Q4 2022 | $202,911,202 | +12.6% | 764,491 | +9.5% | 0.56% | +6.2% |
| Q3 2022 | $180,250,000 | -0.4% | 697,860 | -2.2% | 0.53% | +7.3% |
| Q2 2022 | $180,909,000 | -14.6% | 713,587 | -1.2% | 0.49% | +2.9% |
| Q1 2022 | $211,774,000 | -11.6% | 721,965 | -0.9% | 0.48% | +7.2% |
| Q4 2021 | $239,613,000 | +7.7% | 728,283 | -0.3% | 0.45% | +5.2% |
| Q3 2021 | $222,446,000 | +13.3% | 730,673 | -0.1% | 0.42% | +15.8% |
| Q2 2021 | $196,281,000 | +17.8% | 731,408 | -1.2% | 0.37% | +13.3% |
| Q1 2021 | $166,670,000 | +10.7% | 740,494 | +9.3% | 0.32% | +4.9% |
| Q4 2020 | $150,528,000 | +51.6% | 677,626 | +46.9% | 0.31% | +32.2% |
| Q3 2020 | $99,320,000 | +15.0% | 461,247 | -5.5% | 0.23% | +8.9% |
| Q2 2020 | $86,338,000 | +55.5% | 488,256 | +21.7% | 0.21% | +31.3% |
| Q1 2020 | $55,526,000 | -29.0% | 401,163 | -21.2% | 0.16% | -6.3% |
| Q4 2019 | $78,166,000 | +22.6% | 509,296 | +15.4% | 0.17% | +10.8% |
| Q3 2019 | $63,734,000 | -3.8% | 441,278 | -4.8% | 0.16% | -2.5% |
| Q2 2019 | $66,278,000 | +6.9% | 463,742 | -1.3% | 0.16% | +5.2% |
| Q1 2019 | $62,005,000 | +10.7% | 469,659 | -13.6% | 0.15% | 0.0% |
| Q4 2018 | $56,024,000 | -8.6% | 543,292 | -3.7% | 0.15% | +7.0% |
| Q3 2018 | $61,308,000 | -0.1% | 564,214 | -9.3% | 0.14% | -20.6% |
| Q2 2018 | $61,390,000 | -10.9% | 622,104 | -11.6% | 0.18% | -10.0% |
| Q1 2018 | $68,892,000 | -45.1% | 703,618 | -48.0% | 0.20% | -43.5% |
| Q4 2017 | $125,582,000 | +26.4% | 1,352,963 | +16.8% | 0.35% | +24.2% |
| Q3 2017 | $99,323,000 | +21.6% | 1,157,871 | +19.6% | 0.28% | +21.3% |
| Q2 2017 | $81,699,000 | -10.4% | 968,111 | -9.2% | 0.24% | -9.6% |
| Q1 2017 | $91,166,000 | +5.4% | 1,065,898 | -4.1% | 0.26% | +0.4% |
| Q4 2016 | $86,482,000 | +107.2% | 1,111,026 | +108.6% | 0.26% | +115.8% |
| Q3 2016 | $41,748,000 | +26.4% | 532,563 | +62.9% | 0.12% | +25.0% |
| Q2 2016 | $33,024,000 | +6.4% | 326,977 | -0.1% | 0.10% | 0.0% |
| Q1 2016 | $31,039,000 | +1.8% | 327,206 | -0.3% | 0.10% | -1.0% |
| Q4 2015 | $30,493,000 | +9.2% | 328,301 | +0.2% | 0.10% | +7.8% |
| Q3 2015 | $27,922,000 | -0.7% | 327,689 | -0.3% | 0.09% | +7.1% |
| Q2 2015 | $28,130,000 | +0.4% | 328,658 | -0.4% | 0.08% | -1.2% |
| Q1 2015 | $28,021,000 | -1.6% | 330,042 | -0.7% | 0.08% | -3.4% |
| Q4 2014 | $28,479,000 | +12.8% | 332,269 | +0.0% | 0.09% | +8.6% |
| Q3 2014 | $25,242,000 | -6.0% | 332,210 | -2.6% | 0.08% | -3.6% |
| Q2 2014 | $26,847,000 | -11.1% | 341,012 | -15.3% | 0.08% | -16.8% |
| Q1 2014 | $30,199,000 | -2.4% | 402,644 | +0.5% | 0.10% | -5.6% |
| Q4 2013 | $30,929,000 | +10.8% | 400,630 | -0.5% | 0.11% | -0.9% |
| Q3 2013 | $27,902,000 | -53.5% | 402,500 | -57.5% | 0.11% | -54.4% |
| Q2 2013 | $59,947,000 | – | 947,025 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |